Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.54 |
| ▸ | NT5E | P21589 | 4/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 3/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020651 | 1.00 | PRMT5 (0.54) | PRMT5WDR77NT5EADORA1ADORA2A | |
| SCHEMBL12963636 | 0.84 | ADORA2A (0.64) | NT5EADORA1ADORA2AAHCY | |
| SCHEMBL11684174 | 0.84 | ADORA1 (0.71) | ADORA1ADORA2AAHCYPI4KAPI4K2B | |
| SCHEMBL11684182 | 0.84 | ADORA1 (0.71) | ADORA1ADORA2AAHCYPI4KAPI4K2B | |
| SCHEMBL29832736 | 0.84 | ADORA1 (0.71) | ADORA1ADORA2AAHCYPI4KAPI4K2B | |
| SCHEMBL19128403 | 0.84 | ADORA1 (0.71) | ADORA1ADORA2AAHCYPI4KAPI4K2B | |
| SCHEMBL8626036 | 0.82 | PRMT5 (0.69) | PRMT5WDR77ADORA1ADORA2AAHCY | |
| SCHEMBL29936486 | 0.82 | PRMT5 (0.69) | PRMT5WDR77ADORA1ADORA2AAHCY | |
| SCHEMBL31670485 | 0.82 | ADORA1 (0.61) | NT5EADORA1ADORA2AAHCYPI4KA | |
| SCHEMBL29832131 | 0.82 | ADORA1 (0.61) | NT5EADORA1ADORA2AAHCYPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | PRMT5 501/4885WDR77 2199/4885NT5E 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.